Ipratropium inhalation may also be used for purposes not listed in this medication guide.
Berodual N is a drug made in Czech Republic, Estonia, Georgia, Germany, Hungary, Latvia, Lithuania, Macedonia, Malaysia, Poland, Russian Federation, Serbia, Singapore, Slovakia, Switzerland, Taiwan. You need a doctor's prescription to buy it. But its analogues can be bought online anywhere in the world without going to a specialist.
Ipratropium is a complete analogue of Berodual N. It has the same composition, dosage and methods of use. Also Ipratropium has a lower cost compared to Berodual N.
To buy Berodual N, click on the "buy now" button and then in our online store select the medicine and the desired dosage. Follow the instructions below.
Free delivery is valid for purchases from $200. We deliver medicines around the world and provide the best prices.
You can also use a coupon giving a 5% discount.
Side effects
Severe adverse reactions reported in the study included swelling of your ankles or feet; tremors, nervousness; painful or difficult urination; or wheezing, choking, or other breathing problems after using this medicine; trouble breathing; or headache; blurred vision, tunnel vision, eye pain, or seeing halos around lights; chest pain;
Warnings
Tell your doctor if you have ever had:
- glaucoma;
- an enlarged prostate; or
- bladder obstruction or other urination problems.
Tell your doctor if you are pregnant or breastfeeding.
Interactions
Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. Monitor therapy
Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. Monitor therapy
Anticholinergic Agents: Ipratropium (Oral Inhalation) may enhance the anticholinergic effect of Anticholinergic Agents. Avoid combination
Food interaction
Pregnancy
- Talk to your healthcare provider if you have questions about this risk during pregnancy.
- Fungal nail infection treatment can usually wait until after you have had your baby.
Overview
Interaction
With simultaneous use with anticholinergics, an additive effect occurs.
With simultaneous use, the bronchodilator effect of beta-adrenergic agonists and xanthine derivatives is potentiated.
With the simultaneous use of antiparkinsonian drugs, quinidine, tricyclic antidepressants, the anticholinergic effect of the drug may be enhanced.
With the simultaneous use of this drug with salbutamol, there is a risk of increased intraocular pressure and the development of acute angle-closure glaucoma, especially in susceptible patients.
Questions, answers, reviews on the drug Ipratropium-native
The information provided is intended for medical and pharmaceutical professionals. The most accurate information about the drug is contained in the instructions that are attached to the packaging by the manufacturer. No information posted on this or any other page Berodual our site best way serve as a substitute for a personal appeal to a specialist.
Producer: LLC Nativa Russia
PBX Code: R03BB01
Release form: Liquid dosage forms. Solution for inhalation.
General characteristics. Structure:
Active ingredient: 0.261 mg ipratropium bromide monohydrate in terms of ipratropium bromide 0.25 mg.
Excipients: sodium benzoate, disodium edetate dihydrate (corresponds to disodium edetate), citric acid monohydrate (corresponds to anhydrous citric acid), sodium hydroxide to pH 3.4 ± 0.1, water for injection.
Pharmacological properties:
Pharmacodynamics Ipratropium bromide is a bronchodilating agent that blocks m-cholinergic receptors of the smooth muscles of the tracheobronchial tree and suppresses reflex narrowing of the bronchi (bronchoconstriction). Having structural similarities with the acetylcholine molecule, it is a competitive antagonist. Anticholinergics (m-anticholinergics) prevent an increase in the intracellular concentration of calcium ions, which occurs due to the interaction of acetylcholine with muscarinic receptors located in the smooth muscles of the bronchi. Calcium ions are released via secondary mediators Berodual, which include ITF (inositol triphosphate) and DAG (diacyglycerol).
Ipratropium bromide effectively prevents the narrowing of the bronchi resulting from inhalation of cigarette smoke, cold air, the action of various bronchospasm agents, and also inhibits bronchospasm associated with the influence of the vagus nerve. When inhaled, it practically does not have a resorptive effect. Bronchodilation that occurs after inhalation of ipratropium bromide is mainly a consequence of local and specific effects of the drug on the lungs, another medical not the result of its systemic effect.
After taking ipratropium bromide in patients with bronchospasm due to chronic obstructive pulmonary disease, a significant improvement in lung function is observed within 15 minutes, reaching a maximum after 1-2 hours and lasting up to 4-6 hours.
Pharmacokinetics Suction. After inhalation, 10-30% of the administered dose of ipratropium bromide usually enters the lungs (depending on the dosage form and method of inhalation). Most of the dose is swallowed and enters the gastrointestinal tract.
A portion of the dose of ipratropium bromide entering the lungs quickly reaches the systemic circulation (within a few minutes).
The total component bioavailability of ipratropium bromide, administered orally and inhaled, is 2% and 7-28%, respectively, based on the data that the total renal Berodual (within 24 hours) of the parent compound is approximately 46% of the intravenous dose, less than 1% of the dose used orally and about 3-13% of the inhaled dose of ipratropium bromide.
Distribution
Kinetic parameters describing the distribution of ipratropium bromide were calculated based on its plasma concentrations after intravenous administration. A rapid two-phase decrease in the concentration of ipratropium bromide in the blood plasma is observed. The apparent volume of distribution during the state of equilibrium concentration (Css) is approximately 176 L (≈2.4 L / kg).
